{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:40:39Z","timestamp":1789846839688,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.07.028","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T13:45:53Z","timestamp":1380289553000},"page":"S149-S151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S2","title":["Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?"],"prefix":"10.1016","volume":"22","author":[{"given":"Gunter","family":"von Minckwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Fontanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2013.07.028_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.028_bib2","first-page":"CD005002","article-title":"Preoperative chemotherapy for women with operable breast cancer","volume":"2","author":"Mieog","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.breast.2013.07.028_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djn089","article-title":"Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2013.07.028_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mdi001","article-title":"In\u00a0vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study","volume":"16","author":"von Minckwitz","year":"2005","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.breast.2013.07.028_bib5","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.breast.2013.07.028_bib6","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2013.07.028_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","article-title":"Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials","volume":"125","author":"von Minckwitz","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"24, Suppl.\u00a03","key":"10.1016\/j.breast.2013.07.028_bib8","article-title":"Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)","volume":"72","author":"Cortazar","year":"2012","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.breast.2013.07.028_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-010-1103-9","article-title":"Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study","volume":"124","author":"Huober","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"9712","key":"10.1016\/j.breast.2013.07.028_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.028_bib11","unstructured":"ALTTO (Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimisation) Study; BIG 2-06\/N063D. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00490139 [accessed 04.05.13]."},{"issue":"24, Suppl.\u00a03","key":"10.1016\/j.breast.2013.07.028_bib12","article-title":"Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA)","volume":"71","author":"Schneeweiss","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.07.028_bib13","doi-asserted-by":"crossref","unstructured":"von Minckwitz G, Mamouhdian-Dekordi C, Loibl S, et\u00a0al. Response characteristics and overall survival of 781 patients with triple-negative breast cancer \u2013 a meta-analysis on 7 German neoadjuvant studies. AACR Annual Meeting; 2013.","DOI":"10.1158\/1538-7445.AM2013-4699"},{"key":"10.1016\/j.breast.2013.07.028_bib14","unstructured":"Neoadjuvant treatment of docetaxel, anthracycline and cyclophosphamide (TAC) versus docetaxel and cyclophosphamide (TC) in triple-negative or Her2 positive breast cancer. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00912444 [accessed 04.05.13]."},{"issue":"4","key":"10.1016\/j.breast.2013.07.028_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2013.07.028_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"24, Suppl.\u00a03","key":"10.1016\/j.breast.2013.07.028_bib17","article-title":"Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer","volume":"72","author":"Cameron","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.07.028_bib18","unstructured":"Addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01426880 [accessed 04.05.13]."},{"key":"10.1016\/j.breast.2013.07.028_bib19","unstructured":"Paclitaxel with or without carboplatin and\/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00861705 [accessed 04.05.13]."}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761300163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761300163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:02Z","timestamp":1760776202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097761300163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":19,"alternative-id":["S096097761300163X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.028","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}